Industry News (Patents and Technology)

Broader Patent Protection Obtained for Neupogen

Published in Cancer Weekly, December 16th, 1996

Amgen, Thousand Oaks, California, announced that the U.S. Patent and Trademark Office has issued to the company a patent covering product rights to the recombinant G-CSF or Neupogen (Filgrastim).

The patent provides additional protection against unauthorized making, importation, use, or sale of recombinant G-CSF in the United States. The patent provides 17 years of such protection. Previous patents cover aspects of DNA, vectors, and processes related to recombinant G-CSF.

"This new patent provides additional, broad patent protection and strengthens our intellectual property position on Neupogen," said Gordon Binder, Amgen. Neupogen is licensed in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-12-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry